SANGERA®

Sangera_hirurgiScientific and practical achievements in high-tech medical care in such areas as cardiovascular surgery, transplantation, traumatology, orthopaedics, urology, obstetrics and gynaecology are inextricably related to the problem of blood saving (haemorrhage).

At the same time, the introduction of new haemostatic drugs — systemic antifibrinolytics — into clinical practice greatly enhances clinicians’ possibilities in blood saving technologies.

The product is recommended by the WHO as the first-line drug in prevention and treatment of bleeding in a dose of 1 gram (2 amp. 5 ml 500 mg) every 6–8 hours.

 

How supplied:

5 ml ampoule. 10 ml vial. 10 ml vial. 1 vial + 1 container with solvent agent (sodium chloride-Soluven, 9 mg/ml, 100 ml).

Sales Markets

Tadzhikistan, Uzbekistan, Ukraine.

Download manual Scientific publications

Other Preparations in This Category